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Abstract
Homocysteine, a non-proteinogenic sulfur-containing amino acid, was discovered in 
1932, and 30 years passed until, in 1969, for the first time, its involvement in pathology 
was reported. It was only in the last two decades that homocysteine has become a subject 
of scientific interest and has begun to be intensively studied. A large number of scien-
tists consider homocysteine as an independent risk factor particularly for cardiovascular 
disease, while others indicate homocysteine as a marker of this disease. Both sides bring 
scientific arguments for their opinions, yet the dilemma of homocysteine characterization 
still persists. Although the reported studies do not lead to a unique answer, it is generally 
accepted that homocysteine is associated with vascular dysfunction. Numerous scien-
tific data show that the link between homocysteine and inflammation is achieved via the 
reactive oxygen species (ROS) pathway. The latest data indicate hydrogen peroxide as a 
possible messenger in cellular signaling in physiological or pathological processes and 
present the consequences of disturbing the oxidation-reducing balance. In this chapter, 
we present the latest scientific evidences gathered from the literature for both hypotheses 
regarding homocysteine involvement in pathology, and we propose a possible mecha-
nism of action for homocysteine, based on our preliminary (yet unpublished) work.
Keywords: hyperhomocysteinemia, ROS, inflammation, cell signaling, protein-tyrosine 
phosphatases
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1. Introduction
Homocysteine (Hcy) is a non-proteinogenic amino acid that is formed in the human body 
in methionine metabolism. Although not forming proteins, homocysteine participates in 
major processes such as transmethylation, cysteine (Cys) formation, transsulfuration, etc. In 
the transmethylation process, homocysteine is an intermediate that allows the formation of 
compounds with a major metabolic role such as adrenaline, lecithin, creatine, etc. Cysteine 
formation, via homocysteine, is a very important process because Cys is a vital amino acid to 
stabilize the spatial conformations of proteins, to form the most important antioxidant agent 
in the body named glutathione, or to detoxify harmful compounds.
Over the past 40 years, homocysteine has come to the clinicians’ attention because its high lev-
els in blood have been associated with high risk of mortality and morbidity in many illnesses, 
particularly cardiovascular diseases. Patients with high levels of Hcy, also called hyperhomo-
cysteinemia (HHcy), develop thromboembolism, premature atherosclerosis, mental retarda-
tion, bone fragility, eyes disease, and even miscarriage.
It is obvious that Hcy is related to the pathological phenomenon but the way it intervenes has 
not yet been elucidated. Moreover, there are researchers who believe that homocysteine indi-
cates an already altered state [1] while others consider it a factor triggering the alteration of 
some functions [2]. Both opinions are based on scientific arguments, and although the debate 
continues, most researchers agree that there is an unquestionable link between homocysteine 
and vascular endothelial dysfunction [3–5]. Endothelial dysfunction may have several causes, 
but the major cause is inflammation. Inflammation is the vital process by which organisms 
respond to aggression. In the inflammatory process, a large number of pathways are activated 
to remove aggression and restore homeostasis [6–8]. Complex structures such as cells, pro-
teins, but also small molecules such as reactive species, that are capable of rapidly signaling 
changes in homeostasis, are involved in this process. The activities of these structures need 
to be coordinated, and the latest data indicates that the inflammasome is responsible for this 
task. Recent data have found links between Hcy activity and inflammation [9]. In this chapter 
we present these new data that connect Hcy, inflammation, cell signaling, and reactive species.
As a conclusion, current data indicates Hcy as an amino acid that certainly plays a role in 
pathology, a role that needs to be elucidated.
2. Homocysteine metabolism
A short presentation of the homocysteine metabolism indicates two major pathways of trans-
formation: the transmethylation pathway and the transsulfuration pathway (Figure 1).
Transmethylation pathway converts Hcy to methionine through a chain of reaction that 
involve the participation of methylenetetrahydrofolate reductase (MTHFR), folic acid, vita-
min B12, and methionine synthase (MS).
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Transsulfuration pathway converts Hcy to cystathionine in the presence of the cystathionine 
beta-synthase (CBS) and vitamin B6. Figure 1 highlights the role of tetrahydrofolate (FH4), 
the active form of folic acid, B12, and pyridoxal phosphate (PLP), the active form of vitamin 
B6 in the Hcy metabolism. A minor pathway, not shown in this figure, uses betaine to convert 
homocysteine to methionine.
The general methionine/homocysteine metabolism highlights the two major causes that gen-
erate HHcy: first, the enzymatic deficiencies of the enzymes acting in Hcy metabolization and, 
second, the nutritional deficiencies in vitamin cofactors. This last observation is the base of 
the therapeutic approaches that uses vitamin administration in order to decrease the homo-
cysteine levels.
The normal concentration of homocysteine in human blood is 5–15 μM. HHcy is classified 
according to clinical consequences as being moderate at 16–30 μM, intermediary at 31–100 μM, 
and severe above 100 μM [10]. HHcy caused by the lack of vitamins is not commonly found 
in medical practice and it is easy to cure. The most common cause of HHcy is the enzymatic 
defect of different enzymes acting in this metabolism.
Figure 1. Main pathways of homocysteine transformation.
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3. Homocysteine in pathology
3.1. Cardiovascular diseases
Currently, it is widely accepted that levels of Hcy, even at concentrations slightly higher than nor-
mal, are related to the risk of cardiovascular disease. Clinical studies indicate that a 5 μM increase 
in Hcy levels is equivalent to a 20 mg/dL increase in blood cholesterol [11, 12], which virtually 
doubles the cardiovascular risk. This suggests that between levels of Hcy and atherosclerosis there 
is a better correlation than between the cholesterol levels and atherosclerosis [13, 14]. However 
recent data [2, 15] show that a surprising 30% of cardiovascular mortality occurs in patients who 
do not present conventional risk factors as high LDL, hypertension, smoking, or obesity. This 
raises the question whether Hcy is an independent risk factor or it is a marker of a lesion process.
3.2. Diabetes
Hyperhomocysteinemia is considered a higher risk for patients with diabetes than nondia-
betic patients. An exponential increase in vital risk has been demonstrated in patients pre-
senting HHcy associated to diabetes [16–18]. The increase in Hcy levels noticed in diabetes is 
believed to be due to the degree of diabetes-induced nephropathy [19–21]. Thus, high levels 
of Hcy are found in kidney failure. This data suggest more for a marker role of homocysteine 
rather than a risk factor.
3.3. Neurological diseases
Seshadri [22] has shown that HHcy is associated with Alzheimer’s disease and that it doubles 
the risk of developing the disease in patients with elevated levels of homocysteine as com-
pared to those with normal levels. Although the mechanism that links Hcy to Alzheimer’s is 
unknown, it is supposed that HHcy toxicity to neuronal cells is caused by possible neuronal 
damage following excessive stimulation caused as result of chronic central nervous system 
ischemia [23–25].
3.4. Bone fragility
Increased levels of homocysteine were correlated with increased risk of bone fractures in the 
elderly [26–31]. It seems that Hcy does not affect bone density but rather affects the structure 
of collagen by interfering in the transversal linkages between the collagen fibers. Thus, Hcy 
intervenes in tissue fortification showing more a risk factor role.
3.5. Miscarriage
Research studies notify that HHcy can be generated by the specific mutation in MTHFR. This 
inherited deficiency lead to a 3.3-fold increase in the risk of miscarriage in a sample group 
of 185 Caucasian women [32, 33]. Literature also specifies that associations between MTHFR 
C667T mutations to factor V Leiden and prothrombin gene mutations were identified in 
patients having recurrent miscarriages [34].
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4. Homocysteine involvement in the endothelial function
The presented data show that in high concentration Hcy certainly plays a role in pathology. 
A large number of recent studies indicate that Hcy is an independent risk factor in cardio-
vascular disease [2, 35]. However, other studies indicate Hcy as a marker of this disease [1]. 
Although the reported studies do not lead to a unique answer regarding homocysteine role, 
it is generally agreed that homocysteine is connected to the vascular dysfunction. As a con-
sequence, the investigation of HHcy leads to the investigation of endothelial dysfunction. 
Normal endothelial function consists in maintaining the vascular relaxation and the antico-
agulant status. Any aggression on the endothelial homeostasis leads to changes in vascular 
morphology, tonicity, coagulability, etc. The intensity and time span of aggression determine 
the transition from a normal to a pathogenic transformation.
4.1. Endothelial dysfunction
Vascular endothelium modulates vascular tonicity by secreting a large group of vasoactive 
molecules such as vasodilators (e.g., NO, prostacyclin) and vasoconstrictors (e.g., endothelin, 
thromboxane). The ratio of these compounds showing antagonist action dictates the final vas-
cular tonicity, and under pathological conditions, additional stimulants (mediators of inflam-
mation) cause severe changes in vascular behavior.
Nitric oxide (NO) a natural free radical is synthesized by nitric oxide synthases (NOS) from 
L-arginine by many types of cells including the endothelial cells. Nitric oxide that is synthe-
sized by endothelial nitric oxide synthase (eNOS) promotes vasodilatation; inhibits platelet 
activation, adhesion, and aggregation; prevents smooth muscle proliferation; and modulates 
endothelial-leucocytes interaction [36]. Homocysteine diminishes NO bioavailability through 
various processes that are, at least partially, based on oxidative mechanisms. The current 
literature presents three mechanisms proposed to explain the decrease in NO bioavailabil-
ity in the presence of elevated levels of Hcy. The first mechanism indicates that Hcy reacts 
with nitric oxide to form S-nitroso-homocysteine [36, 37]. The second one considers that NO 
bioavailability is blocked by sequestration following reactions with other radical species. 
NO is trapped by superoxide to form peroxynitrite, thus being inactivated [38, 39]. The third 
mechanism assumes that NO synthesis is decreased by NO-synthase inhibition by asymmet-
ric dimethylarginine (ADMA), a potent inhibitor of the enzyme produced by the degradation 
of methylated proteins [40]. Increased ADMA concentration was identified in an HHcy status 
[41]. These mechanisms are found widely presented in our previous work [42].
Eicosanoids represent a group of compounds directly involved in vascular function. They act 
as paracrine hormones and mediate the inflammatory response. This group includes prosta-
cyclin (PGI2), a compound with vasodilating activity, and thromboxane TXA2, a compound 
with vasoconstrictive activity. Prostacyclin or prostaglandin PGI2, produced by epithelial 
cells, prevents platelet aggregation, decreases proliferation of smooth muscle cells, decreases 
pro-inflammatory cytokines (↓IL-1 and IL6), and exerts antimitogenic activity (↓VEGF and 
TGF-β). On contrary TXA2 promote the thrombosis and vascular constriction. In the chain of 
reactions that generates eicosanoids, some are of the oxidative type so they generate reactive 
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species. Thus, the balance between these paracrine hormones is very important for the vas-
cular homeostasis. Research data show that HHcy is considered as a factor that prevents 
vasodilation, promotes vasoconstriction, and increases the risk of thrombosis, thus inducing 
vascular injuries [43]. In vitro studies have demonstrated that HHcy induces the release of 
arachidonic acid, precursor of eicosanoids, including TXA2 [44].
Endothelins are vasoconstricting peptides mainly produced by the endothelium. They constrict 
blood vessel promoting high blood pressure. In addition to its vasoconstrictor effects, isoform 
endothelin-1 (ET-1) influences cell growth, thus being involved in atherosclerosis. Epithelial 
cells regulate ET-1 levels in response to hypoxia, oxidized species of LDL, or pro-inflammatory 
cytokines. Endothelins (ET-1, ET-2, ET-3) act on two receptors that have different locations 
and whose activation triggers different effects: vasoconstrictive effect through ETA receptors 
located in smooth muscle cells [45] and vasodilation and NO release through ET
B
 receptors 
located on endothelial cells. Recent data show that HHcy results in the upregulation of ETA 
receptor expression and high blood pressure in rats [46] while decreasing ET-1 production 
in endothelial cells, thus impairing NO and prostacyclin production and consequently the 
vasodilatation [47]. Thus, HHcy disturbs the ratio between vasodilators and vasoconstrictors 
promoting endothelial dysfunction [48].
5. Homocysteine mechanism of action
In the endothelial dysfunction, the inflammation process is a key step, and the reactive species 
are present at the site of inflammation, playing multiple roles, including defense, annihilation, 
or cellular signaling. In this chain of events, HHcy interferes somewhere with the endothe-
lial normal function. There are several generally accepted mechanisms for Hcy-dependent 
endothelial dysfunction: reactive oxygen species [49], inflammatory response [50], or thrombotic 
phenomenon [51]. These mechanisms will be presented below along with scientific evidence 
for each of them.
5.1. Hyperhomocysteinemia involvement in oxidative stress
Numerous researches point ROS as the potential mediators for the effects of HHcy. 
Generation of reactive species is considered to trigger a cascade of events leading to release 
of pro-inflammatory cytokines, activation of adhesion molecules, generation of intracel-
lular messengers that activate intracellular enzymes, and cellular responses including gene 
activation/repression [52–54]. Many studies demonstrate that HHcy generates reactive 
species directly or through autoxidation [55, 56]. ROS species found in HHcy was indi-
rectly assessed through the measurement of antioxidative enzyme activity [57–59]. In our 
previous work, we have found that HHcy triggers the generation of hydrogen peroxide 
and that high levels of homocysteine experimentally induced (by methionine loading in 
rat) diminish more the total antioxidant capacity inside the erythrocytes rather than in 
plasma [60, 61].
Non-Proteinogenic Amino Acids38
5.2. Hyperhomocysteinemia involvement in inflammation
Recent studies [7, 8] had advanced the idea that Hcy triggers vascular damage by promoting an 
inflammatory response followed by immediate effects on the vascular wall or by delayed effects 
on proteins and DNA structures. The inflammatory phenomenon represents the vascular tis-
sue response to lesion agents (chemical/physical or biological) [6]. The inflammatory response 
consists in two actions: removal of the lesion agent and initiation of the healing process. The 
acute inflammation predominates the local vascular response characterized by the presence of 
fast-acting and low half-life components (leucocytes). In the chronic inflammation, there is a 
progressive change in the types of cells present at the lesion site, characterized by the dominant 
presence of macrophages. The crucial phase is the destruction of pathogens. This phase takes 
place in monocytes/macrophages and neutrophils in the respiratory burst where the reactive 
oxygen species are generated. ROS are as damaging to pathogens as they are to the host’s tis-
sue. Consequently, chronic inflammation is accompanied by tissue destruction. Macrophages/
neutrophils are not the site for respiratory burst only, but they also secret and/or trigger the 
secretion of specific compounds such as cytokines. The discovery of interleukins had intro-
duced the concept of systemic inflammation. This type of inflammation is characterized by the 
fact that tissue destruction is not limited to a certain tissue but involves endothelium and other 
organs also. In systemic inflammation, elevated levels of chemical mediators such as interleu-
kins (IL-6, IL-8, and TNFα) are associated with atherosclerosis and diabetes [62–64]. Recently, 
it has been found that HHcy is associated to inflammatory markers IL-6 and TNFα [65–68].
The cells of the innate immune system continually survey the extracellular environment in 
order to detect the “danger” signal. To achieve this function, immune cells develop receptors 
that act as sensors for the “invaders.” Following the foreign detection, a group of actions must 
be initiated and coordinated, task being undertaken by the inflammasome. Inflammasomes 
are key signaling platforms that act as a checkpoint that controls and regulates the inflam-
matory response. It consists of multi-protein complexes that assemble by pattern-recognition 
receptors after the detection of a “danger “signal in the cytosol of the host cell. The protein 
association represents the activation stage of the inflammasome that triggers the signal of 
inflammation which is the caspase 1 and caspase 11 activation. Activated caspases initiate the 
highly pro-inflammatory cytokines’ interleukin-1β (IL-1β) and IL-18 production, and finally 
an inflammatory form of cell death termed pyroptosis is triggered. The intracellular control of 
the inflammasome assembly is exerted via ion fluxes, free radicals, and autophagy. Latest data 
indicate the inflammasome activation as a possible mechanism for homocysteine involvement 
in inflammation and in programmed cell death in endothelial cells [69]. Current literature also 
demonstrates that the activation of inflammasomes (NLRP3 complex) represent a key step in 
HHcy-aggravated atherosclerosis [9].
5.3. Hyperhomocysteinemia involvement in thrombogenesis
HHcy promotes thrombosis by a mechanism that integrates the already presented processes 
of oxidation and decreases the NO bioavailability with the modification of some specific pro-
teins acting in the coagulation and fibrinolysis pathway. Literatures show that homocysteine 
initiates structural modifications of these proteins, modifications that will impair their normal 
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functions. Such proteins include the tissue plasminogen activator (tPA), atherogenic factor 
lipoprotein(a) (Lp(a)), the complex thrombomodulin-thrombin, and DNA proteins.
The tPA is a serine protease that converts plasminogen to fibrinolytic protein plasmin. Hcy 
forms disulfide bridge with annexin II (an important receptor for tissue plasminogen activa-
tor in endothelium), thus blocking tPA binding to this protein. As a result, tPA activity is 
impaired, plasmin generation is diminished, and fibrinolysis activity is decreased [70].
Activation of plasminogen depends on the binding of fibrin as a cofactor. Lipoprotein (a) is 
an atherogenic lipoprotein which competitively binds to fibrin, thus preventing activation of 
plasminogen. Hcy favors lipoprotein-a binding to fibrin, which ultimately leads to decreased 
fibrinolysis [71]. HHcy added to a dyslipidemia profile results in increased risk of thrombosis.
Protein C is another serine protease present in blood as zymogen. Upon activation it exerts 
important role in anticoagulation, inflammation, and also cell death. The complex thrombo-
modulin-thrombin activates protein C, thus inhibiting the thrombotic process. Hcy impairs 
the complex thrombomodulin-thrombin activity by forming disulfide bridges with both 
thrombomodulin and protein C. As a consequence, the thrombotic process is promoted [72]. 
These mechanisms are found widely presented in our previous work [42].
5.4. Hyperhomocysteinemia involvement in cellular signaling
The survival of the cell is by default linked to its ability to remove any type of aggression/lesion 
and to restore the initial healthy structure. In this process, cells develop a network of systems that 
is capable to communicate, to mobilize defense/healing structures, or to memorize information 
about the type of aggression. In this process, complex structures and small molecules are equally 
involved, together being able to signal any changes in homeostasis. Reactive species of oxygen and 
nitrogen as well as active peptides (cytokines) produced at the site of inflammation by neutrophils 
or monocytes/macrophages are small molecules capable of rapid signaling. They promote vascu-
lar changes and open the inter-endothelial junctions thus allowing the migration of inflammatory 
cells across the endothelial barrier. All the activities related to inflammatory response are coor-
dinated by chemical signaling through reactive species signals or active peptides (cytokine) [73].
The link between reactive species and inflammation is now well documented. On the other 
hand, current data associate Hcy with both inflammation and reactive species. The factor that 
puts together all these components is not fully elucidated. Over the past two decades, many 
scientific evidences show that ROS serve in physiological as well as pathological processes 
[74, 75]. Normal levels of reactive species act as signaling molecules to regulate biological 
and physiological processes, while their accumulation is strongly associated with oxidative 
stress [76]. Current scientific data indicate that among reactive oxygen species hydrogen per-





 could mimic growth factor activity and that the growth factors could stimulate 




 within cells. [78–80]. A major role in cell signaling that 
promotes cell proliferation, nutrient uptake, and cell survival is realized by the activation of 
the protein-tyrosine kinases class which includes both tyrosine kinases (Src, Ras, JAK2, Pyk2, 
PI3K) and mitogen-activated protein kinases (MAPK) (Figure 2).
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These signal transduction pathways use receptors with intrinsic tyrosine kinase activity 
(RTK) which leads to the phosphorylation of specific tyrosine residues located on tyrosine 
kinase proteins. Literatures show that hydrogen peroxide is required for optimal activation 
of protein-tyrosine kinases [85]. In the same time, hydrogen peroxide transiently inhibit 
protein-tyrosine phosphatases (PTPs) through the reversible oxidization of their catalytic 
cysteine [86], thus suppressing protein-tyrosine kinases dephosphorylation [87]. Thus, 
the activity of MAPK kinases is negatively regulated by protein-tyrosine phosphatases as 
depicted in Figure 3.
Protein-tyrosine phosphatases are specific proteins that contain cysteine residues at their 
active site. These enzymes remove a phosphate group attached to a tyrosine residue (such in 
MAP kinases), using a cysteinyl-phosphate enzyme intermediate. Latest literature data [88, 89] 
show that the activity of protein-tyrosine phosphatases is regulated by the reversible oxida-
tion of cysteine residues. In the reversible oxidation, the PTPs activity results in temporar-
ily dampening of mitogenic signaling [84, 90]. Protein-tyrosine phosphatases can suffer 




 levels, [91]. As 
a result, their function is blocked and the mitogen signal remains continuously activated 
(Figure 3).
Cysteine is unique among the amino acids because it is the only proteinogenic amino acid 





mediated oxidation of cysteine residues within proteins [92]. During redox signaling low/




 (nM range) oxidizes the thiol group of cysteine residues to 




 gradually increases, the sulfenic form 
Figure 2. General signal pathway activated by ROS (modified from [81]), PKC = protein kinase, MAPK = mitogen-
activated protein, JNK = c-Jun N-terminal kinases, ERK = extracellular signal-regulated kinases, NFκB = nuclear factor 
κB, AP-1 = activator protein-1, HIF-1 = hypoxia-inducible factor-1 C [42]. More details about the cellular response in ROS 
and other radical and nonradical species attack on oxidative events can be found in [82–84].
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transforms to sulfinic (SO
2
H) and sulfonic (SO
3
H) forms, respectively. Unlike sulfenic modi-





 can trigger the irreversible oxidation of cysteine group.




 generator according to scientific 
data, may interfere in this signaling process promoting mitogenic activity.
Moreover, Hcy is very similar in structure to cysteine. Like cysteine, Hcy is an amino acid 
containing a free SH group. This makes possible the occurrence of disulfide bridges between 
the two amino acids similar to those existing between cysteine residues in some particular 
concentration of hydrogen peroxide. In our opinion (preliminary work, unpublished data), 
this may be a possible mechanism of homocysteine involvement in cell signaling that must be 
investigated (Figure 4).
All the scientific evidence presented above suggest Hcy as a risk factor for the vascular/endo-
thelial dysfunction.
Instead some scientists investigate Hcy from the opposite point of view [93] and consider 
HHcy as a marker of an already altered vascular state rather than a risk factor. These authors 









, PTPs becomes 
irreversibly inactive and, as a consequence, tyrosine kinase proteins involved in cell proliferation (MAPK) remain 
blocked on active form. TRK = receptors with intrinsic tyrosine kinase activity; and PTP = proteon-tyrosine phosphatases.
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consider that hypertension and atherosclerosis reach the stage where kidney function is sev-
erally impaired and Hcy removal is diminished and, consequently, its concentration rises in 
the blood. Atherosclerosis and hypertension are silent diseases that develop years before a 
vascular event occurs. The disease is accompanied by a silent decline in renal function and, 
as a consequence, total clearance including that of homocysteine diminishes. Thus, vascular 
disease contributes to the elevation of circulating Hcy as result of the progressive decline in 
renal function, and HHcy in fact reflects the severity of atherosclerosis. Thus, HHcy becomes 
a signal that the atherosclerotic disease reaches an irreversible stage.
Regardless of the classification of homocysteine as a risk factor or marker, its involvement in 
pathology is certain, and its role needs to be elucidated.
6. Conclusion
The study of homocysteine began when its association with cardiovascular disease was dis-
covered. Further studies revealed its association with vascular dysfunction, and then Hcy was 
linked to the inflammatory phenomenon. Recently, as studies advanced, the homocysteine 
involvement in inflammation has been identified. The inflammatory process in turn is related 
Figure 4. Possible mechanism for hyperhomocysteinemia to intercept the protein-tyrosine phosphatase regulation 
through disulfide bridge formation. TRK = receptors with intrinsic tyrosine kinase activity; PTP = proteon-tyrosine 
phosphatases; and HHcy = hyperhomocysteinemia.
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to the activity of reactive species, and recent data indicate protein-tyrosine phosphatases as key 
factors in regulating intracellular signaling pathways. These proteins allow regulation because 
they can undergo reversible oxidation phenomena due to the presence in their structure of 
cysteine residues bearing SH groups. The structural similarity of Cys with homocysteine 
draws attention to the possibility that Hcy may interfere with cysteine functions. In conclu-
sion, the recent association of Hcy with both inflammation and the reactive species involved 
in cellular signaling indicates that homocysteine remains a topic of interest and attention in 
current research. It is obvious that HHcy is an issue of interest in contemporary medicine.
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